Prevention of acute mountain sickness by acetazolamide in Nepali porters: A double-blind controlled trial

Wilderness and Environmental Medicine

Volumn 17, Issue 2, 2006, Pages 87-93

  Hillenbrand, Peter ^a,e   Pahari, Anil K ^b   Soon, Yuen ^c,d   Subedi, Deepak ^b   Bajracharya, Rajan ^b   Gurung, Puncho ^b   Lal, Barun K ^b   Marahatta, Ramesh ^b   Pradhan, Santosh ^b   Rai, Dilip ^b   Sharma, Shailendra ^b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b TRIBHUVAN UNIVERSITY TEACHING HOSPITAL   (Nepal)

^c Queen Elizabeth Hospital   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e NONE   (United Kingdom)

Author keywords

Acclimatization; Acetazolamide prophylaxis; Acute mountain sickness; Altitude; Nepali porters

Indexed keywords

ACETAZOLAMIDE; PLACEBO;

ADULT; ALTITUDE ACCLIMATIZATION; ALTITUDE DISEASE; ARTICLE; BIRTHPLACE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIURESIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPAL; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 33745173128     PISSN: 10806032     EISSN: None     Source Type: Journal    
DOI: 10.1580/1080-6032-17.2.87     Document Type: Article

References (14)

1. Hackett PH, Rennie D. The incidence, importance and prophylaxis of acute mountain sickness. Lancet. 1976;2:1149-1155.
2. Dubowitz G, Miller D. A reduction in the incidence of acute mountain sickness and high altitude pulmonary oedema at 4250 m in Nepal. 12th International Hypoxia Symposium, March 10-14, 2001, Jasper, Alberta, Canada [abstract 65]. High Alt Med Biol 2001;2:1.A65.
3. Basnyat B, Litch JA. Medical problems of porters and trekkers in the Nepal Himalayas. Wilderness Environ Med. 1997;8:273-274.
4. Basnyat B, Le Master J. Risk of altitude sickness in Nepalese porters in the Everest Region. J Inst Med. 2001;24:137-143.
5. Forwand SA, Landowne M, Follansbee JN, Hansen JE. Effect of acetazolamide on acute mountain sickness. N Engl J Med. 1968;279:16.839-845.
6. Birmingham Medical Research Expeditionary Society Mountain Sickness Study Group. Acetazolamide in control of acute mountain sickness. Lancet. 1981;1:180-183.
7. Hillenbrand P, Wright A, Beazley M, Imray C, Major R, Bradwell AR. Clinical observations on acetazolamide prophylaxis in Nepalese porters. 12th International Hypoxia Symposium, March 10-14, 2001, Jasper, Alberta, Canada [abstract 103]. High Alt Med Biol. 2001;2:1.A103.
8. Roach RC, Maes D, Sandoval D, et al. Exercise exacerbates acute mountain sickness at simulated high altitude. J Appl Physiol. 2000;88:581-585.
9. Nepal Agricultural Research Council. 25 Years of Rice Research in Nepal (1972-1997) National Rice Research Programme. Parwanipur, Bara, Nepal; 1997:1 and 13.
10. Nepal Agricultural Research Council (NARC Newsletter). A Special Issue on International Year of Rice-2004. Communication, Publication and Documentation Division (NARC): Khumaltar, Lalitpur, Nepal; May 2004:4.
11. Roach RC, Bärtsch P, Hackett PH, Oelz O. The Lake Louise acute mountain sickness scoring system. In: Sutton JR, Houston CS, Coates G, eds. Hypoxia and Mountain Medicine. Burlington, VT. Queen City Press; 1993:272-274.
12. Basnyat B, Gertsch JH, Johnson EW, Castro-Marin F, Inoue Y, Yeh C. Efficacy of low-dose acetazolamide (125 mg b.i.d.) for the prophylaxis of acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial. High Alt Med Biol. 2003;4:1.45-52.
13. Basnyat B, Gertsch JH, Jo EW Acetzolamide 125 mg b.i.d. is as effective as 375 mg b.i.d. in the prevention of acute mountain sickness (the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial). 14th International Hypoxia Symposium, Feb 22-27, 2005; Chateau Lake Louise, Canada [abstract 5]. High Alt Med Biol. 2004;5:4.475.A5.
14. Ward MP, Milledge JS, West JB. Rate of ascent. In: High Altitude Medicine and Physiology. 3rd ed. London: Arnold; Copublished in New York: Oxford University Press; 2001:226.